Clinical Trial Update: Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

View source ↗

Summary

Expanded access protocol for patisiran in hereditary transthyretin-mediated amyloidosis has been approved for marketing, enabling broader patient access.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis

Drugs mentioned

• Patisiran (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis, Amyloidosis, Hereditary | Status: APPROVED_FOR_MARKETING